Emapalumab

CAS No. 1709815-23-5

Emapalumab( —— )

Catalog No. M36694 CAS No. 1709815-23-5

Emapalumab (NI-0501) is an IgG1 monoclonal antibody that humanizes human monoclonal antibodies against interferon gamma, blocking its binding to cell surface receptors and activating inflammatory signaling.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 519 In Stock
10MG 846 In Stock
25MG 1302 In Stock
50MG 1702 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Emapalumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Emapalumab (NI-0501) is an IgG1 monoclonal antibody that humanizes human monoclonal antibodies against interferon gamma, blocking its binding to cell surface receptors and activating inflammatory signaling.
  • Description
    Emapalumab (NI-0501) is a humanized monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH).
  • In Vitro
    Emapalumab (NI-0501) impairs IFNcR1 and IFNc-Receptor-2 (IFNcR2) interaction induced by IFNc at the cell surface.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    COX
  • Recptor
    COX
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1709815-23-5
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Vallurupalli M, et, al. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood. 2019 Nov 21;134(21):1783-1786.?
molnova catalog
related products
  • Mofezolac

    Mofezolac (formerly known as Disopain or N-22) is a highly selective COX-1 (cyclooxygenase-1) inhibitor with COXs selectivity index > 6000.

  • Oxyphenbutazone

    Oxyphenbutazone is a non-selective COX inhibitor. Oxyphenbutazone is a phenylbutazone derivative.

  • Valdecoxib

    Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about possible increased risk of heart attack and stroke.